STOCKHOLM, Sept. 20, 2022 /PRNewswire/ Updated 12-month results from the open-label investigator-initated Phase II clinical trial GADinLADA that assessed three intralymphatic injections of
STOCKHOLM, July 7, 2022 /PRNewswire/ The primary endpoints of safety and tolerability were met in the open-label investigator-initiated Phase II clinical trial GADinLADA, in which the diabetes
/PRNewswire/ The primary endpoints of safety and tolerability were met in the open-label investigator-initiated Phase II clinical trial GADinLADA, in which.